The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma
Open accessAbstract
Aberrant c‐Met activity has been implicated in the development of hepatocellular carcinoma (HCC), suggesting that c‐Met inhibition may have therapeutic potential. However, clinical trials of nonselective kinase inhibitors with c‐Met activity (tivantinib, cabozantinib, foretinib, and golvatinib) in patients with HCC have failed so far to demonstrate significant efficacy. This lack of observed efficacy is likely due to several factors, including trial design, lack of patient selection according to tumor c‐Met status, and the prevalent off‐target activity of these agents, which may indicate that c‐Met inhibition is incomplete. In contrast, selective c‐Met inhibitors (tepotinib, capmatinib) can be dosed at a level predicted to achieve complete inhibition of tumor c‐Met activity. Moreover, results from early trials can be used to optimize the design of clinical trials of these agents. Preliminary results suggest that selective c‐Met inhibitors have antitumor activity in HCC, with acceptable safety and tolerability in patients with Child‐Pugh A liver function. Ongoing trials have been designed to assess the efficacy and safety of selective c‐Met inhibition compared with standard therapy in patients with HCC that were selected based on tumor c‐Met status. Thus, c‐Met inhibition continues to be an active area of research in HCC, with well‐designed trials in progress to investigate the benefit of selective c‐Met inhibitors. (H epatology 2018;67:1132–1149)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Self-citationTargeting MET in cancer: rationale and progress
Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3205 · Cited by 1,423
Yakes, F. M., Chen, J., Tan, J., Yamaguchi, K., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,336
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
MET signalling: principles and functions in development, organ regeneration and cancer
Trusolino, L., Bertotti, A., & Comoglio, P. M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3012 · Cited by 1,240
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Semenza, G. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00518-9 · Cited by 935
Frampton, G. M., Ali, S. M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T. M., Akimov, M., Bufill, J. A., Lee, C., Jentz, D., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0285 · Cited by 796 · cited 2×
“1%.((78)) Other activating MET mutations are also rare, detectable only in childhood HCCs((79)); and most HCCs that express high levels of c-Met receptor have neither amplified nor mutated MET.”
BackgroundYau, T., Park, J. W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Han, K.-H., Harding, J. J., Merle, P., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.029 · Cited by 647
Self-citationSantoro, A., Rimassa, L., Borbath, I., Daniele, B., Salvagni, S., Van Laethem, J. L., Van Vlierberghe, H., Trojan, J., Kolligs, F. T., Weiss, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70490-4 · Cited by 554
Invasive growth: a MET-driven genetic programme for cancer and stem cells
Boccaccio, C., & Comoglio, P. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1912 · Cited by 538
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Eder, J. P., Vande Woude, G. F., Boerner, S. A., & LoRusso, P. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1306 · Cited by 522
Met provides essential signals for liver regeneration
Borowiak, M., Garratt, A. N., Wüstefeld, T., Strehle, M., Trautwein, C., & Birchmeier, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403412101 · Cited by 497
Hepatocyte growth factor twenty years on: Much more than a growth factor
Nakamura, T., Sakai, K., Nakamura, T., & Matsumoto, K. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06549.x · Cited by 470
Munshi, N., Jeay, S., Li, Y., Chen, C.-R., France, D. S., Ashwell, M. A., Hill, J., Moussa, M. M., Leggett, D. S., & Li, C. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1173 · Cited by 326
Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
Goyal, L., Muzumdar, M. D., & Zhu, A. X. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2791 · Cited by 307
Liu, X., Wang, Q., Yang, G., Marando, C., Koblish, H. K., Hall, L. M., Fridman, J. S., Behshad, E., Wynn, R., Li, Y., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1157 · Cited by 265
Chen, J., Jin, R., Zhao, J., Liu, J., Ying, H., Yan, H., Zhou, S., Liang, Y., Huang, D., Liang, X., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.019 · Cited by 251
Park, W. S., Dong, S. M., Kim, S. Y., Na, E. Y., Shin, M. S., Pi, J. H., Kim, B. J., Bae, J. H., Hong, Y. K., Lee, K. S., et al. (1999) · PubMed · Cited by 251
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Raoul, J., Zeuzem, S., Poulin-Costello, M., Moscovici, M., Voliotis, D., & Bruix, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.lba1 · Cited by 237
Xiang, Q., Chen, W., Ren, M., Wang, J., Zhang, H., Deng, D. Y. B., Zhang, L., Shang, C., & Chen, Y. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2620 · Cited by 229
Targeting the HGF/Met signaling pathway in cancer therapy
Cecchi, F., Rabe, D. C., & Bottaro, D. P. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.680957 · Cited by 222
Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients
Greten, T. F., Papendorf, F., Bleck, J. S., Kirchhoff, T., Wohlberedt, T., Kubicka, S., Klempnauer, J., Galanski, M., & Manns, M. P. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602590 · Cited by 194
Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials
Kudo, M. (2017) · Oncology · doi:10.1159/000451016 · Cited by 194
You, H., Ding, W., Dang, H., Jiang, Y., & Rountree, B. C. (2011) · Hepatology · doi:10.1002/hep.24450 · Cited by 185
Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment
Janevska, D., Chaloska-Ivanova, V., & Janevski, V. (2015) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2015.111 · Cited by 178
Angiogenesis and the Tumor Microenvironment: Vascular Endothelial Growth Factor and Beyond
Mittal, K., Ebos, J. M. L., & Rini, B. I. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.007 · Cited by 162
Pathophysiology of Liver Fibrosis
Pinzani, M. (2015) · Digestive Diseases · doi:10.1159/000374096 · Cited by 160
Hepatocyte growth factor: A regulator of inflammation and autoimmunity
Molnarfi, N., Benkhoucha, M., Funakoshi, H., Nakamura, T., & Lalive, P. H. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.11.013 · Cited by 159
Met as a therapeutic target in HCC: Facts and hopes
Giordano, S., & Columbano, A. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.009 · Cited by 158
c-Met as a Target for Personalized Therapy
Garajová, I., Giovannetti, E., Biasco, G., & Peters, G. J. (2015) · Translational Oncogenomics · doi:10.4137/tog.s30534 · Cited by 146
EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
Bladt, F., Faden, B., Friese‐Hamim, M., Knuehl, C., Wilm, C., Fittschen, C., Grädler, U., Meyring, M., Dorsch, D., Jaehrling, F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3247 · Cited by 140
Gavine, P. R., Ren, Y., Han, L., Lv, J., Fan, S., Zhang, W., Xu, W., Liu, Y. J., Zhang, T., Fu, H., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.08.015 · Cited by 125
Kataoka, Y., Mukohara, T., Tomioka, H., Funakoshi, Y., Kiyota, N., Fujiwara, Y., Yashiro, M., Hirakawa, K., Hirai, M., & Minami, H. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9699-0 · Cited by 118
Liu, L., Zeng, W., Wortinger, M. A., Yan, S., Cornwell, P. D., Peek, V. L., Stephens, J. R., Tetreault, J. W., Xia, J., Manro, J. R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0543 · Cited by 111
Verslype, C., Cohn, A. L., Kelley, R. K., Yang, T., Su, W., Ramies, D. A., Lee, Y., Shen, X., & Cutsem, E. V. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.4007 · Cited by 108
Nakagawa, T., Tohyama, O., Yamaguchi, A., Matsushima, T., Takahashi, K., Funasaka, S., Shirotori, S., Asada, M., & Obaishi, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01343.x · Cited by 106
Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?
Finn, R. S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2084 · Cited by 99
GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells
Rix, L. L. R., Kuenzi, B. M., Luo, Y., Remily-Wood, E. R., Kinose, F., Wright, G. M., Li, J., Koomen, J. M., Haura, E. B., Lawrence, H. R., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400660a · Cited by 93
Marquardt, J. U., Seo, D., Gómez-Quiroz, L. E., Uchida, K., Gillen, M. C., Kitade, M., Kaposi-Novák, P., Conner, E. A., Factor, V. M., & Thorgeirsson, S. S. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.02.012 · Cited by 91
Santoro, A., Simonelli, M., de Lope, C. R., Zucali, P. A., Camacho, L. H., Granito, A., Senzer, N. N., Rimassa, L., Abbadessa, G., Schwartz, B. E., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.556 · Cited by 81
Zhang, S., Pan, F., Xu, J., Yuan, J. J., Guo, S.-Y., Dai, G., Xue, B., Shen, W., Wen, C., Zhao, D., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0106 · Cited by 81
Goldman, J. W., Laux, I., Chai, F., Savage, R. E., Ferrari, D., Garmey, E. G., Just, R. G., & Rosen, L. S. (2012) · Cancer · doi:10.1002/cncr.27575 · Cited by 78
Yau, T. C. C., Lencioni, R. A., Sukeepaisarnjaroen, W., Chao, Y., Yen, C.-J., Lausoontornsiri, W., Chen, P., Sanpajit, T., Camp, A., Cox, D. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1789 · Cited by 78
Liu, L., Shi, H., Liu, Y., Anderson, A. E., Peterson, J. J., Greger, J., Martin, A., & Gilmer, T. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0698 · Cited by 74
Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future Directions
Choi, K., Baik, I. H., Ye, S., & Lee, Y.-H. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00231 · Cited by 68
The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models
Bladt, F., Friese‐Hamim, M., Ihling, C. H., Wilm, C., & Blaukat, A. (2014) · Cancers · doi:10.3390/cancers6031736 · Cited by 64
A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma.
Lee, S. J., Lee, J., Sohn, I., et al. (2013) · PubMed · Cited by 63
Aoyama, A., Katayama, R., Oh‐hara, T., Sato, S., Okuno, Y., & Fujita, N. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0462 · Cited by 63
MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
Qi, X. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i18.5445 · Cited by 60
Sangro, B., Park, J., Cruz, C. M. D., Anderson, J., Lang, L., Neely, J., Shaw, J. W., & Cheng, A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.tps4147 · Cited by 60
Self-citationLigand‐independent activation of MET through IGF‐1/IGF‐1R signaling
Varkaris, A. S., Gaur, S., Parikh, N. U., Song, J. H., Dayyani, F., Jin, J., Logothetis, C. J., & Gallick, G. E. (2013) · International Journal of Cancer · doi:10.1002/ijc.28169 · Cited by 59
Puzanov, I. J., Sosman, J. A., Santoro, A., Saif, M. W., Goff, L. W., Dy, G. K., Zucali, P. A., Means-Powell, J. A., Ma, W. W., Simonelli, M., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0167-5 · Cited by 59
Huynh, H. T., Ong, R., & Soo, K. C. (2011) · Angiogenesis · doi:10.1007/s10456-011-9243-z · Cited by 56
Noguchi, O., Enomoto, N., Ikeda, T., Kobayashi, F., Marumo, F., & Sato, C. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80006-7 · Cited by 56
Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance
Dietrich, C. G. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.72 · Cited by 50
Bang, Y., Su, W., Nam, D., Lim, W., Bauer, T. M., Braña, I., Poon, R. T. P., Hong, D. S., Lin, C., Peng, B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2520 · Cited by 45
Sangro, B., Melero, I., Yau, T. C., Hsu, C., Kudo, M., Crocenzi, T. S., Kim, T., Choo, S., Trojan, J., Meyer, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.4078 · Cited by 42
Xin, Y., Jin, D., Eppler, S., Damico‐Beyer, L. A., Joshi, A., Davis, J. D., Kaur, S., Nijem, I., Bothos, J. G., Peterson, A., et al. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.148 · Cited by 39
Cheng, A., Kang, Y., Chen, Z., Tsao, C., Qin, S., Kim, J., Burock, K., Zou, J., Voliotis, D., & Guan, Z. Z. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4509 · Cited by 36
Self-citationIntegrative biomarker analyses indicate etiological variations in hepatocellular carcinoma
Zhu, A. X., Chen, D., He, W., Kanai, M., Voi, M., Chen, L., Daniele, B., Furuse, J., Kang, Y., Poon, R. T. P., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.015 · Cited by 34
Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist
Fasolo, A., Sessa, C., Gianni, L., & Broggini, M. (2012) · Annals of Oncology · doi:10.1093/annonc/mds520 · Cited by 30
Ang, C., Miura, J. T., Gamblin, T. C., He, R., Xiu, J., Millis, S. Z., Gatalica, Z., Reddy, S. K., Yee, N. S., & Abou‐Alfa, G. K. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.24086 · Cited by 29
Trends in the Development of Met Inhibitors for Hepatocellular Carcinoma
Okuma, H. S., & Kondo, S. (2016) · Future Oncology · doi:10.2217/fon.16.3 · Cited by 29
Du, Z., Caenepeel, S. R., Shen, Y., Rex, K. L., Zhang, Y., He, Y., Tang, E., Wang, O., Zhong, W., Zhou, H., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0745 · Cited by 22
Inoue, H., Yokoyama, F., Kita, Y., Yoshiji, H., Tsujimoto, T., Deguchi, A., Nakai, S., Morishita, A., Uchida, N., Masaki, T., et al. (2006) · International Journal of Molecular Medicine · doi:10.3892/ijmm.17.5.857 · Cited by 21
Kwon, J., Lee, N., Park, J. Y., Yu, Y. S., Kim, J. P., Shin, J. H., Kim, D., Joh, J., Kim, D. S., Choi, K. Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064260 · Cited by 19
Advances in the study of molecularly targeted agents to treat hepatocellular carcinoma
Chen, J., & Gao, J. (2014) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2014.01031 · Cited by 13
Johnson, P. J. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e132 · Cited by 7
Roberts, L. R., & Wheeler, D. A. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-3745 · Cited by 2
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
New advances in the diagnosis and management of hepatocellular carcinoma
Yang, J. D., & Heimbach, J. K. (2020) · BMJ · doi:10.1136/bmj.m3544 · Cited by 384
Molecular therapies for HCC: Looking outside the box
Faivre, S., Rimassa, L., & Finn, R. S. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.010 · Cited by 326
Self-citationGajos-Michniewicz, A., & Czyz, M. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.050 · Cited by 89
Metadata
- Authors
- Bouattour, M., Raymond, E., Qin, S., Cheng, A., Stammberger, U., Locatelli, G., & Faivre, S.
- Venue
- Hepatology
- Published
- 2018-02-01
- Volume
- 67
- Issue
- 3
- Pages
- 1132-1149
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2750691704
- Cited by
- 257
- References
- 76
- FWCI
- 14.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.